Alcohol and the Brain; The Next Alzheimer’s Frontier; Mice With Human Brain Cells

The New York Times looked at what alcohol does to the brain and what amount, if any, may be safe.

Ongoing phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease showed continued slowing of disease progression, but effects were not significant at 4 years compared with a natural history cohort, uniQure said.

Epilepsy incidence rose sharply after symptomatic Alzheimer’s disease onset in people with Down syndrome, an international longitudinal study showed. (The Lancet)

Tau-targeting drugs may be the next frontier in Alzheimer’s disease treatment, with an expected value as high as $70 billion, an investment banking firm reported. (Axios)

Transient ischemic attacks were associated with a large and sustained increase in dementia risk in a Canadian cohort study. (Neurology)

Stroke rates among younger adults ages 20 to 54 nearly doubled over a 27-year period in a large U.S. study, coinciding with increases in both vascular risk factors and substance abuse. (Neurology)

DNL343, a brain-penetrant drug designed to inhibit the integrated stress response, did not show benefit in amyotrophic lateral sclerosis (ALS), data from the HEALEY ALS platform trial showed. (JAMA Network Open)

The nervous systems of mice engineered to lack a cerebral cortex successfully integrated transplanted human stem cell-derived cortical organoids. (Nature)

Two women who provided autism therapy services were arrested and charged with defrauding the Connecticut Medicaid Health Insurance Program, according to the state’s division of criminal justice.